Hence, navitoclax combined with dasatinib produces synergistic outcomes against AML cells co-expressing NUP98-NSD1 and FLT3-ITD, in which navitoclax inhibits the BCL-2A1 while dasatinib suppresses the proteins Lck and Fgr [83]. The gene discussed is FLT3; the disease is acute myeloid leukemia.